公开(公告)号：WO2011082388A3

公开(公告)日：2011-07-07

申请号：PCT/US2011/000001

申请日：2011-01-03

申请人： MEDIGEN, INC . ,  PUSHKO, Peter ,  TRETYAKOVA, Irina ,  LUKASHEVICH, Igor

发明人： PUSHKO, Peter ,  TRETYAKOVA, Irina ,  LUKASHEVICH, Igor

IPC分类号： A61K39/12 ,  A61P31/14

摘要： Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

公开(公告)号：WO2010008576A2

公开(公告)日：2010-01-21

申请号：PCT/US2009/004133

申请日：2009-07-17

申请人： MEDIGEN, INC. ,  PUSHKO, Peter ,  LUKASHEVICH, Igor

发明人： PUSHKO, Peter ,  LUKASHEVICH, Igor

IPC分类号： A61K48/00

CPC分类号： A61K39/193 ,  A61K39/12 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/85 ,  C12N2770/24134 ,  C12N2770/24161 ,  C12N2770/36134 ,  C12N2770/36161 ,  Y02A50/388

摘要： Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

摘要翻译： 本文描述的是iDNA载体和疫苗及其使用方法。 iDNA在真核细胞中在体外或体内在致病性RNA病毒，特别是黄热病病毒和委内瑞兰马脑炎病毒中产生减毒疫苗。 当将iDNA注射到疫苗接受者中时，活体减毒病毒的RNA通过受体组织中的体内转录产生。 这启动了疫苗接受者组织中后代减毒病毒的产生，以及引发保护免受野生型非减毒病毒的有效免疫应答。

公开(公告)号：WO2018098133A1

公开(公告)日：2018-05-31

申请号：PCT/US2017/062733

申请日：2017-11-21

申请人： MEDIGEN, INC.

发明人： PUSHKO, Peter ,  TRETYAKOVA, Irina

IPC分类号： C12N5/10 ,  C12N7/00 ,  C12N15/11 ,  C12N15/85

摘要： Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.

公开(公告)号：WO2017004586A1

公开(公告)日：2017-01-05

申请号：PCT/US2016/040838

申请日：2016-07-01

申请人： MEDIGEN, INC.

发明人： PUSHKO, Peter ,  TRETYAKOVA, Irina

IPC分类号： A61K39/145 ,  C12N7/00 ,  C12N7/01

CPC分类号： A61K39/12 ,  A61K2039/5258 ,  C12N7/00 ,  C12N2740/14034 ,  C12N2740/16023 ,  C12N2760/16134

摘要： Described herein are Bovine immunodeficiency virus gag protein ("Bgag") recombinant virus like particles ("VLPs") comprising one or more different types of target pathogen proteins. Also described, are compositions comprising the novel Bgag VLPs and the methods of making and using the novel Bgag VLPs.

摘要翻译： 本文描述了包含一种或多种不同类型的靶病原体蛋白的牛免疫缺陷病毒gag蛋白（“Bgag”）重组病毒样颗粒（“VLP”）。 还描述了包含新型Bgag VLP的组合物和制备和使用新型Bgag VLP的方法。

公开(公告)号：WO2011082388A2

公开(公告)日：2011-07-07

申请号：PCT/US2011000001

申请日：2011-01-03

申请人： MEDIGEN INC ,  PUSHKO PETER ,  TRETYAKOVA IRINA ,  LUKASHEVICH IGOR

发明人： PUSHKO PETER ,  TRETYAKOVA IRINA ,  LUKASHEVICH IGOR

IPC分类号： A61K48/00

CPC分类号： A61K39/12 ,  A61K49/0004 ,  A61K2039/5254 ,  A61K2039/53 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/36121 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36151

摘要： Described herein are i-DNATM vectors and vaccines and methods for using the same. The i-DNATM generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

摘要翻译： 本文描述了i-DNATM载体和疫苗以及使用它们的方法。 i-DNATM在体外或体内真核细胞中产生致病RNA病毒特别是基孔肯雅病毒（CHIKV）的减毒活疫苗。 当iDNA被注射到疫苗接受者体内时，活的减毒病毒的RNA通过在受体组织中的体内转录产生。 这启动了疫苗接受者组织中子代减毒病毒的产生，以及引发针对野生型非减毒病毒的有效免疫应答。

公开(公告)号：WO2010008576A3

公开(公告)日：2010-04-29

申请号：PCT/US2009004133

申请日：2009-07-17

申请人： MEDIGEN INC ,  PUSHKO PETER ,  LUKASHEVICH IGOR

发明人： PUSHKO PETER ,  LUKASHEVICH IGOR

IPC分类号： C12N15/65 ,  A61K48/00 ,  C12N5/00

CPC分类号： A61K39/193 ,  A61K39/12 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/85 ,  C12N2770/24134 ,  C12N2770/24161 ,  C12N2770/36134 ,  C12N2770/36161

摘要： Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

摘要翻译： 本文描述了iDNA载体和疫苗以及使用它们的方法。 iDNA在体外或体内真核细胞中产生病毒RNA病毒，特别是黄热病病毒和委内瑞拉马脑炎病毒的减毒活疫苗。 当iDNA被注射到疫苗接受者体内时，活的减毒病毒的RNA通过在受体组织中的体内转录产生。 这启动了疫苗接受者组织中子代减毒病毒的产生，以及引发针对野生型非减毒病毒的有效免疫应答。